Delayed and prolonged histone hyperacetylation with a selective HDAC1/HDAC2 inhibitor

ACS Medicinal Chemistry Letters

Volumn 5, Issue 4, 2014, Pages 340-345

  Methot, Joey L ^a   Hoffman, Dawn Mampreian ^a   Witter, David J ^a   Stanton, Matthew G ^a   Harrington, Paul ^a   Hamblett, Christopher ^a   Siliphaivanh, Phieng ^a   Wilson, Kevin ^a   Hubbs, Jed ^a   Heidebrecht, Richard ^a   Kral, Astrid M ^a   Ozerova, Nicole ^a   Fleming, Judith C ^a   Wang, Hongmei ^a   Szewczak, Alexander A ^a   Middleton, Richard E ^a   Hughes, Bethany ^a   Cruz, Jonathan C ^a   Haines, Brian B ^a   Chenard, Melissa ^a   Kenific, Candia M ^a   Harsch, Andreas ^a   Secrist, J Paul ^a   Miller, Thomas A ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Histone acetylation; histone deacetylase inhibitor; isoform selectivity; kinetics

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR; SELECTIVE HISTONE DEACETYLASE 1 2 INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING KINETICS; CANCER INHIBITION; CELL CULTURE; DRUG BINDING; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HISTONE ACETYLATION; HISTONE HYPERACETYLATION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

EID: 84898032526     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml4004233     Document Type: Article

References (25)

1. Zhang, Y.; Fang, H.; Jiao, J.; Xu, W. The structure and function of histone deacetylases: the target for anti-cancer therapy Curr. Med. Chem. 2008, 15, 2840-2849
2. Yang, X.-J.; Seto, E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men Nat. Rev. Mol. Cell Biol. 2008, 9, 206-218
3. Miller, T. A.; Witter, D. J.; Belvedere, S. Histone deacetylase inhibitors J. Med. Chem. 2003, 46, 5097-5116
4. Paris, M.; Porcelloni, M.; Binaschi, M.; Fattori, D. Histone deacetylase inhibitors: from bench to clinic J. Med. Chem. 2008, 51, 1505-1529
5. Bieliauskas, A. V.; Pflum, M. K. H. Isoform-selective histone deacetylase inhibitors Chem. Soc. Rev. 2008, 37, 1402-1413
6. Spiegel, S.; Milstien, S.; Grant, S. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy Oncogene 2011, 31, 537-551
7. Knoepfler, P. S.; Eisenman, R. N. Sin meets NuRD and other tails of repression Cell 1999, 99, 447-450
8. Lagger, G.; O'Carroll, D.; Rembold, M.; Khier, H.; Tischler, J.; Weitzer, G. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression EMBO J. 2002, 21, 2672-2681
9. Huang, B. H.; Laban, M.; Leung, C. H.; Lee, L.; Lee, C. K.; Salto-Tellez, M. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1 Cell Death Differ. 2005, 12, 395-404
10. Weihert, W.; Roske, A.; Gekeler, V.; Beckers, T.; Stephan, C.; Jung, K.; Fritzsche, F. R.; Niesporek, S.; Denkert, C.; Dietel, M.; Kristiansen, G. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy Br. J. Cancer 2008, 98, 604-610
11. Bonfils, C.; Walkinshaw, D. R.; Besterman, J. M.; Yang, X.-J.; Li, Z. Pharmacological inhibition of histone deacetylases for the treatment of cancer, neurodegenerative disorders and inflammatory diseases Expert Opin. Drug Discovery 2008, 3, 1041-1065
12. Methot, J. L.; Hamblett, C. L.; Mampreian, D. M.; Jung, J.; Harsch, A.; Szewczak, A. A.; Dahlberg, W. K.; Middleton, R. E.; Hughes, B.; Fleming, J. C.; Wang, H.; Kral, A. M.; Ozerova, N.; Cruz, J. C.; Haines, B.; Chenard, M.; Kenific, C. M.; Secrist, J. P.; Miller, T. A. SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2) Bioorg. Med. Chem. Lett. 2008, 18, 6104-6109
13. For enzyme and cell assay protocols, see Hamblett, C. L.; Methot, J. L.; Mampreian, D. M.; Sloman, D. L.; Stanton, M. G.; Kral, A. M.; Fleming, J. C.; Cruz, J. C.; Chenard, M.; Ozerova, N.; Hitz, A. M.; Wang, H.; Deshmukh, S. V.; Nazef, N.; Harsch, A.; Hughes, B.; Dahlberg, W. K.; Szewczak, A. A.; Middleton, R. E.; Mosley, R. T.; Secrist, J. P.; Miller, T. A. The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 5300-5309
14. Witter, D. J.; Harrington, P.; Wilson, K. J.; Fleming, J. C.; Kral, A. M.; Secrist, J. P.; Miller, T. A. Optimization of biaryl selective HDAC1&2 inhibitors (SHI-1:2) Bioorg. Med. Chem. Lett. 2008, 18, 726-731
15. Methot, J. L.; Chakravarty, P. K.; Chenard, M.; Close, J.; Cruz, J. C.; Dahlberg, W. K.; Fleming, J.; Hamblett, C. L.; Hamill, J. E.; Harrington, P.; Harsch, A.; Heidebrecht, R.; Hughes, B.; Jung, J.; Kenific, C. M.; Kral, A. M.; Meinke, P. T.; Middleton, R. E.; Ozerova, N.; Sloman, D. L.; Stanton, M. G.; Szewczak, A. A.; Tyagarajan, S.; Witter, D. J.; Secrist, J. P.; Miller, T. A. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2) Bioorg. Med. Chem. Lett. 2008, 18, 973-978
16. Moradei, O. M.; Mallais, T. C.; Frechette, S.; Paquin, I.; Tessier, P. E.; Leit, S. M.; Fournel, M.; Bonfils, C.; Trachy-Bourget, M.-C.; Liu, J.; Yan, T. P.; Lu, A.-H.; Rahil, J.; Wang, J.; Lefebvre, S.; Li, Z.; Vaisburg, A. F.; Besterman, J. M. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity J. Med. Chem. 2007, 50, 5543-5546
17. Montgomery, R. L.; Potthoff, M. J.; Haberland, M.; Qi, X.; Matsuzaki, S.; Humphries, K. M.; Richardson, J. A.; Bassel-Duby, R.; Olson, E. N. Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice J. Clin. Invest. 2008, 118, 3588-3597
18. Warrener, R.; Chia, K.; Warren, W. D.; Brooks, K.; Gabrielli, B. Inhibition of histone deacetylase 3 produces mitotic defects independent of alterations in histone H3 lysine 9 acetylation and methylation Mol. Pharmacol. 2010, 78, 384-393
19. Chenard, M.; Close, J.; Cruz, J.; Deshmukh, S.; Fleming, J.; Grimm, J.; Haines, B.; Hamblett, C.; Harrington, P.; Harsch, A.; Heidebrecht, R.; Hitz, A.; Hubbs, J.; Hughes, B.; Jung, J.; Kattar, S.; Kral, A. M.; Kenific, C.; Mampreian, D.; Methot, J.; Middleton, R.; Otte, K.; Ozerova, N.; Siliphaivanh, P.; Sloman, S.; Stanton, M.; Surdi, L.; Szewczak, A.; Wang, H.; Wilson, K.; Witter, D.; Secrist, P.; Miller, T. Prolonged Histone Hyperacetylation with a Novel Class of HDAC1/2 Selective Inhibitors, Abstract 5433; American Association for Cancer Research, Washington, D.C., April 17-21, 2010
20. Chou, C. J.; Herman, D.; Gottesfeld, J. M. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases J. Biol. Chem. 2008, 283, 35402-35409
21. Bonfils, C.; Kalita, A.; Dubay, M.; Siu, L. L.; Carducci, M. A.; Reid, G.; Martell, R. E.; Besterman, J. M.; Li, Z. Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay Clin. Cancer Res. 2008, 14, 3441-3449
22. Fournel, M.; Bonfils, C.; Hou, Y.; Yan, P. T.; Trachy-Bourget, M.-C.; Kalita, A.; Liu, J.; Lu, A.-H.; Zhou, N. Z.; Robert, M.-F.; Gillespie, J.; Wang, J. J.; Ste-Croix, H.; Rahil, J.; Lefebvre, S.; Moradei, O.; Delorme, D.; MacLeod, A. R.; Besterman, J. M.; Li, Z. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo Mol. Cancer Ther. 2008, 7, 759-768
23. Zhou, N.; Moradei, O.; Raeppel, S.; Leit, S.; Frechette, S.; Gaudette, F.; Paquin, I.; Bernstein, N.; Bouchain, G.; Vaisburg, A.; Jin, Z.; Gillespie, J.; Wang, J.; Fournel, M.; Yan, P. T.; Trachy-Bourget, M.-C.; Kalita, A.; Lu, A.; Rahil, J.; MacLeod, A. R.; Li, Z.; Besterman, J. M.; Delorme, D. Discovery of N -(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor J. Med. Chem. 2008, 51, 4072-4075
24. Berk, S. C.; Close, J.; Hamblett, C.; Heidebrecht, R. W.; Kattar, S. D.; Kliman, L. T.; Mampreian, D. M.; Methot, J. L.; Miller, T.; Sloman, D. L.; Stanton, M. G.; Tempest, P.; Zabierek, A. A. Spirocyclic compounds as HDAC inhibitors. WO 2007/061978.
25. A comparative in vitro and in vivo analysis of vorinostat and compound 2 (also known as MRLB-223) has recently been reported by Johnstone et al. See Newbold, A.; Matthews, G. M.; Bots, M.; Cluse, L.; Clarke, C. J. P.; Banks, K.-M.; Cullinane, C.; Bolden, J. E.; Christiansen, A. J.; Dickins, R. A.; Miccolo, C.; Chiocca, S.; Kral, A. M.; Ozerova, N. D.; Miller, T. A.; Methot, J. L.; Richon, V.; Secrist, J. P.; Minucci, S.; Johnstone, R. W. Molecular and biological analysis of histone deacetylase inhibitors with diverse specificities Mol. Cancer Ther. 2013, 12, 2709-2721